Vital Therapies names Faheem Hasnain as chairman

SKIN_Faheem_Hasnain_t575.jpg

Vital Therapies (NASDAQ:VTL) appointed Faheem Hasnain as chairman, effective immediately.

Mr. Hasnain succeeds co-chairmen, Terry Winters, who is CEO of Vital, and Muneer Satter, both of whom will remain on the board, with Dr. Winters remaining as CEO. Mr. Hasnain also remains as chairman of the board’s commercialization committee.

“Faheem’s deep experience and proven track record of success in the pharmaceutical industry will be instrumental in guiding Vital Therapies through its next chapter of development, which includes completion of the VTL-308 Phase 3 trial, regulatory filings and commercialization, if the trial is successful,” Mr. Satter said in a statement.

Mr. Hasnain served as president, CEO and a director of Receptos from 2010 to 2015. He also was president, CEO and a director of PDL BioPharma in 2008. Mr. Hasnain is currently chairman of Tocagen and Sente, and also serves on the board of Kura Oncology.